Sep 07, 2022 / 03:20PM GMT
Yigal Dov Nochomovitz - Citigroup Inc. Exchange Research - Research Analyst
Good morning, everyone. My name is Yigal Nochomovitz. I'm one of the biotech analysts here at Citi, joined by my colleague, Neena Garg. So we're here to talk about rare diseases. We have 3 outstanding companies to engage with from Ultragenyx, Eric Crombez, Chief Medical Officer of Ultragenyx Gene Therapy; from Decibel Therapeutics, Laurence Reid, CEO; and from Rocket Pharma, Gaurav Shah, also CEO. We'll try to keep it more of a high-level discussion, but I do want to give each of you just a very quick 2 or 3 minutes just to give everyone a quick overview of the company, what are the key assets, potentially key data points over the next to 2 months and then we can go into more of a discussion about rare disease drug development.
Eric Crombez -
Great. Thanks for the opportunity. Again, I'm Eric Crombez, so I'm the Chief Medical Officer for Ultragenyx Gene Therapy and Inborn Errors of Metabolism programs. Been with Ultragenyx for about 5 years now and really founded and dedicated to the treatment of
Rocket Pharmaceuticals Inc, Decibel Therapeutics Inc and Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference- Panel Transcript
Sep 07, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers